Shares of Dynavax Technologies Co. (NASDAQ:DVAX) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $16.50.
A number of brokerages have issued reports on DVAX. BidaskClub raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. William Blair reaffirmed a “buy” rating on shares of Dynavax Technologies in a report on Friday, August 16th. Finally, Zacks Investment Research raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Wednesday.
Several hedge funds have recently bought and sold shares of the company. Morgan Stanley boosted its stake in Dynavax Technologies by 298.0% during the 2nd quarter. Morgan Stanley now owns 473,794 shares of the biopharmaceutical company’s stock worth $1,890,000 after purchasing an additional 354,760 shares during the last quarter. Swiss National Bank boosted its holdings in Dynavax Technologies by 4.2% in the second quarter. Swiss National Bank now owns 119,078 shares of the biopharmaceutical company’s stock valued at $475,000 after purchasing an additional 4,800 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Dynavax Technologies in the second quarter valued at approximately $59,000. DekaBank Deutsche Girozentrale increased its stake in Dynavax Technologies by 32.3% in the second quarter. DekaBank Deutsche Girozentrale now owns 532,000 shares of the biopharmaceutical company’s stock valued at $2,054,000 after purchasing an additional 130,000 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in Dynavax Technologies by 103.2% in the second quarter. UBS Asset Management Americas Inc. now owns 1,741,907 shares of the biopharmaceutical company’s stock valued at $6,950,000 after purchasing an additional 884,854 shares during the last quarter. 82.36% of the stock is currently owned by institutional investors and hedge funds.
Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.10). The firm had revenue of $10.58 million during the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative net margin of 519.95% and a negative return on equity of 399.60%. Dynavax Technologies’s revenue was up 624.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.65) earnings per share. On average, sell-side analysts predict that Dynavax Technologies will post -2.04 earnings per share for the current fiscal year.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Recommended Story: The limitations of an equal weight rating
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.